BeiGene News | Markets Insider

GlobeNewswire 1,828d

BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia

Seeking Alpha 1,828d

EC accepts BeiGene application for Brukinsa for rare blood cancer

Seeking Alpha 1,834d

BeiGene antibodies show positive action on blood cancers

GlobeNewswire 1,834d

BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress

GlobeNewswire 1,841d

BeiGene to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

GlobeNewswire 1,843d

BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle...

Seeking Alpha 1,843d

BeiGene's zanubrutinib OK'd in China for blood cancers

GlobeNewswire 1,848d

BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical...

GlobeNewswire 1,848d

BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology...

GlobeNewswire 1,851d

BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program

Seeking Alpha 1,851d

Chi-Med and Beigene collaborate to evaluate cancer candidates

GlobeNewswire 1,856d

BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA™ (zanubrutinib) in Israel

GlobeNewswire 1,857d

BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference

GlobeNewswire 1,862d

BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

GlobeNewswire 1,863d

BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress

GlobeNewswire 1,866d

BeiGene Reports First Quarter 2020 Financial Results

GlobeNewswire 1,877d

BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

InvestorPlace 1,884d

This Stock Points to the Massive China Biotech Trend

GlobeNewswire 1,887d

BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China

GlobeNewswire 1,894d

BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free...

GlobeNewswire 1,896d

China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

GlobeNewswire 1,913d

BeiGene Announces Supply Update for ABRAXANE® in China

InvestorPlace 1,922d

7 Biotech Stocks to Buy and Hold in 2020

GlobeNewswire 1,936d

BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire 1,942d

BeiGene to Present at the Cowen and Company’s 40th Annual Health Care Conference

Seeking Alpha 1,946d

Key events next week - healthcare

Moodys 1,949d

Amgen Inc. -- Moody's assigns Baa1 rating to Amgen's new sr. unsecured notes; stable outlook

Reuters 1,977d

UPDATE 1-BeiGene lung cancer treatment improves progression-free survival

Reuters 1,977d

BeiGene lung cancer treatment meets main goal in late-stage study

GlobeNewswire 1,977d

BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free...

GlobeNewswire 1,985d

EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA®▼ in Greater China

GlobeNewswire 1,990d

BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 1,996d

BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment

GlobeNewswire 2,001d

China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Classical Hodgkin’s Lymphoma Who Have Received at Least Two Prior Therapies

GlobeNewswire 2,006d

BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID® in Relapsed or Refractory Indolent Lymphoma

Reuters 2,013d

UPDATE 2-BeiGene cancer drug fails in study against AbbVie-J&J's Imbruvica

Reuters 2,013d

UPDATE 1-BeiGene drug fails comparative study against AbbVie-J&J rival Imbruvica

Reuters 2,013d

BeiGene drug fails main goal in late-stage study against AbbVie-J&J rival Imbruvica

GlobeNewswire 2,013d

BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia

GlobeNewswire 2,016d

BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019

GlobeNewswire 2,020d

BeiGene Announces Clinical Data on BRUKINSA™ (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting

GlobeNewswire 2,033d

BeiGene to Present at the 31st Annual Piper Jaffray Healthcare Conference

InvestorPlace 2,034d

The Most Overlooked Investment Theme Heading Into 2020

GlobeNewswire 2,036d

BeiGene Announces Clinical Data on Tislelizumab Presented at European Society for Medical Oncology (ESMO) Asia 2019 Congress

InvestorPlace 2,040d

7 Catalysts Pointing to Massive Potential in Chinese Biotech Stocks

InvestorPlace 2,040d

Chinese Biotech Stocks: The 100X Play as Big Pharma Money Moves In

Reuters 2,043d

BeiGene prices lymphoma drug at $12,935 for a 30-day supply

Reuters 2,044d

UPDATE 2-China's BeiGene gets FDA approval for drug to treat rare form of lymphoma

GlobeNewswire 2,044d

U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy

Reuters 2,045d

UPDATE 1-BeiGene drug wins U.S. FDA approval for rare form of lymphoma

News for BeiGene Ltd (spons. ADRs)